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AbstrAct
Objective To determine characteristics associated with 
monthly chest pain and shortness of breath (SoB) during 
activity in cardiovascular disease (CVD) and trajectories of 
these symptoms over 10 months.
Study design and setting Baseline questionnaire was 
sent to patients aged ≥40 years from 10 UK general 
practices. Responders were sent monthly questionnaires 
for 10 months. For patients with CVD (ischaemic 
heart disease and heart failure), the association of 
sociodemographic characteristics, pain elsewhere and 
anxiety and depression with monthly reports of chest pain 
and SoB during activity were determined using multilevel, 
multinomial logistic regression. Common symptom 
trajectories were determined using dual trajectory latent 
class growth analysis.
Results 661 patients with CVD completed at least 
5 monthly questionnaires. Multiple other pain sites 
(relative risk ratio: 4.03; 95% CI 1.64 to 9.91) and anxiety 
or depression (relative risk ratio: 3.31; 95% CI 1.89 to 
5.79) were associated with reporting weekly chest pain. 
Anxiety or depression (relative risk ratio: 4.10; 95% CI 
2.72 to 6.17), obesity (relative risk ratio: 2.53; 95% CI 
1.49 to 4.30), older age (80+: relative risk ratio: 2.51; 
95% CI 1.19 to 5.26), increasing number of pain sites (4+: 
relative risk ratio: 4.64; 95% CI 2.35 to 9.18) and female 
gender (relative risk ratio: 1.81; 95% CI 1.20 to 2.75) were 
associated with reporting weekly SoB. Eight symptom 
trajectories were identified, with SoB symptoms more 
common than chest pain.
Conclusions Potentially modifiable characteristics are 
associated with the experience of chest pain and SoB. 
Identified symptom trajectories may facilitate tailored care 
to improve outcomes in patients with CVD.
IntroductIon
Chest pain and shortness of breath (SoB) are 
common symptoms of cardiovascular disease 
(CVD) seen in UK primary care. The inci-
dence of chest pain ranges between 13 and 20 
per 1000 person-years,1–3 with chest pain 
consultation being a risk factor for future 
cardiovascular morbidity and mortality.2 4 
SoB is a frequent symptom of heart failure 
(HF) and angina.5 6 Patients with CVD may 
experience and consult for chest pain and 
SoB separately, while many patients will expe-
rience both together.7
Though directly associated with CVD, chest 
pain and SoB may also be experienced due to 
non-cardiac reasons. In a US sample of 10 881 
participants with no prevalent CVD or pulmo-
nary conditions, 22% reported SoB,8 and SoB 
and chest pain have been shown to be associ-
ated with other patient characteristics such as 
age, gender and depression.9 Understanding 
potentially modifiable patient characteristics 
associated with the symptoms of chest pain 
and SoB (whether related to CVD pathology) 
in patients diagnosed with CVD may present 
additional opportunities to direct manage-
ment to reduce the risk of disease progression 
and prolonged symptom experience and to 
improve outcomes in patients with CVD.
Symptoms of chest pain and SoB are 
not typically isolated events. Assessing how 
patients’ symptoms co-occur and change over 
time may help identify common patterns 
(trajectories) of these symptoms that may 
be related to long-term outcomes. However, 
how the experience of chest pain and SoB in 
patients with CVD varies over time remains 
unclear. Other trajectories of symptoms have 
previously been determined to aid under-
standing of the course of morbidity, for 
example, in back pain.10 Understanding the 
different trajectories of patient symptoms 
can be beneficial when trying to optimise 
healthcare resources, for example, through 
stratified care.11 Such methods may allow 
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Strengths and limitations of this study 
 ► This was a large study of primary care patients with 
diagnosed cardiovascular (CVD) disease.
 ► It is the first study to examine the course of CVD 
symptoms based on monthly self-reported data.
 ► There was attrition, with many patients not 
completing sufficient monthly questionnaires to be 
included in the analysis.
 ► Due to the nature of the questionnaire data, we were 
unable to identify the number or the duration of the 
monthly symptom episodes.
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better targeting of interventions, potentially earlier or to 
those with greater need.
The objectives of our study, in a primary care popula-
tion with CVD, were; (1) to determine the association of 
patient characteristics with the monthly experience of 
chest pain or SoB during activity and (2) to determine 
common trajectories of chest pain and SoB symptoms 
over time.
Methods
study design
This analysis uses data from the Comorbidity Cohort 
(2C) study. A prospective cohort study, this was designed 
to investigate the interaction between CVD and osteo-
arthritis (OA) comorbidity over 12 months. Full details 
of the 2C study are reported elsewhere.12–14 In brief, the 
2C study sampled patients with recorded cardiovascular 
morbidity and/or OA, aged 40 years or older, plus a 
reference group without CVD or OA, from the electronic 
health records of 10 UK general practices. All patients 
fulfilling the study inclusion criteria were mailed a base-
line questionnaire, which included measures of general 
health as well as CVD and OA specific measures. Those 
who completed the baseline questionnaire and consented 
to further follow-up were mailed shorter monthly health 
questionnaires for the following 10 months and a larger 
questionnaire at 12 months.
study population
This analysis focuses only on those patients with recorded 
CVD (with or without comorbid OA) of which there were 
2858 sent a baseline questionnaire. These patients were 
identified through a primary care record of ischaemic 
heart disease (IHD) or HF using Read codes (commonly 
used to record morbidity in UK primary care) within a 
3-year period prior to the baseline questionnaire, starting 
from November 2006. IHD was identified by Read codes 
starting G3 (‘Ischaemic heart disease’), and HF was iden-
tified by Read codes starting G58 (‘Heart failure’) and 
codes related to the New York Heart Association classifi-
cation (codes 662f-i).
outcome measures
The primary outcomes were monthly self-reported 
measures of two CVD-related symptoms: (1) chest pain 
during activity and (2) SoB during activity. A single-item 
question was used for each symptom, both based on 
existing, valid outcome measures (the Seattle Angina 
Questionnaire15 and the Kansas City Cardiomyopathy 
Questionnaire)16. Patients were asked ‘How often (if at 
all) have you had chest pain during activity over the past 
4 weeks?’. The same question structure was used for SoB. 
Response options for these questions were ‘Not at all’, 
‘For 1 week or less’, ‘For 2 weeks’, ‘For 3 weeks’ and ‘For 
4 weeks. For analysis, these were categorised into: ‘not at 
all’, ‘for 1–3 weeks’ and ‘for 4 weeks’, representing no, 
episodic and persistent monthly symptoms, respectively.
covariates
Covariates measured in the baseline questionnaire were 
age, gender, body mass index (BMI; based on self-re-
ported height and weight), general physical health, pain 
elsewhere and anxiety and depression. BMI was catego-
rised as: normal weight (<25), overweight (25–30) or 
obese (30+). General physical health was measured using 
the 12-item Short-Form Health Survey.17 From this, the 
Physical Component Summary (PCS) score was derived; 
this is normalised to the US general population with 
scores below 50 reflecting worse physical health than for 
the general population. Anxiety and depression were 
measured using the Hospital Anxiety and Depression 
Scale with the possible score ranging from 0 (best) to 21 
(worst) for anxiety and for depression.18 Given the strong 
association between anxiety and depression, we combined 
the two scales and defined those with borderline or prob-
able anxiety or depression (based on standard cut-offs) as 
anxious or depressed. We determined the extent of pain 
elsewhere at baseline as a count of 10 self-reported areas 
of pain (neck, shoulder, elbow, hand, back, hip, knee, 
foot, abdominal and headache). This was categorised 
into none, 1–3, and 4 or more sites. Lacey et al19 suggested 
the number of self-reported pain sites is more important 
than the pain location.19
Baseline chest pain and SoB were measured using yes/
no responses to items enquiring about any chest pain or 
tightness in the past 4 weeks, and any SoB in the past 4 
weeks.
statistical analyses
The statistical analysis was performed in two phases. 
The first phase examined associations between baseline 
sample characteristics and monthly chest pain and SoB 
experienced during activity. The second phase clustered 
patients into groups based on the most common patterns 
(trajectories) of chest pain and SoB experienced over the 
10-month follow-up time period. Responders who had 
completed chest pain or SoB items on at least 5 of the 
10 monthly questionnaires were included in the analyses.
Phase one: associations between baseline characteristics, chest 
pain and SoB
A multilevel, multinomial logistic regression model 
(monthly measurements nested within respondents) 
was used to determine associations between the baseline 
sample characteristics (age, gender, BMI, general phys-
ical health, pain elsewhere, anxiety and depression) 
and monthly chest pain during activity (1–3 weeks vs 
none and 4+ weeks vs none). Associations were initially 
unadjusted, followed by adjustment for covariates. PCS 
score was not included in the multivariable model due 
to strong association with age and pain elsewhere. Inter-
actions between time and covariates that were found to 
be statistically significant were incorporated into the 
model to assess whether their effects changed over the 
time period. The same analysis was then repeated for 
SoB.
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Sensitivity analyses were performed using respondents 
who completed the chest pain and SoB items on at least 
2 monthly questionnaires and by using multiple imputa-
tion (with 50 imputations) to impute the missing monthly 
questionnaire answers and any missing covariate data.
Phase two: chest pain and SoB cluster trajectories
Dual trajectory latent class growth analysis (LCGA) was 
carried out to group (cluster) respondents into the most 
common trajectories of self-reported chest pain and SoB 
over the 10 months using the repeated monthly measures 
of the two symptoms.20 Each cluster, therefore, represents 
a common trajectory of both chest pain and SoB over 
the 10 months. A fundamental assumption behind dual 
trajectory LCGA is that the two symptoms, in this case, 
chest pain and SoB, are correlated. The time order of the 
measurements were taken into account when deriving 
the trajectories within a cluster by using quadratic growth 
curves.
There is no definitive method of deciding on the most 
appropriate number of clusters using statistical goodness 
of fit measures. We initially used Akaike’s information 
criterion, Bayesian information criterion (BIC) and the 
adjusted BIC, and for each of these, the model with the 
lowest goodness of fit value indicates the optimal number 
of clusters. The final decision on the optimal number of 
clusters was determined by a combination of statistical 
information, the size and distinctiveness of the clusters 
and how well the profile (monthly responses of chest pain 
and SoB) of respondents matched the cluster . Respon-
dents were allocated to the cluster for which they had the 
highest posterior probability of belonging. The mean of 
these posterior probabilities for respondents assigned to 
each cluster (ie,  cluster-specific average posterior prob-
abilities (AvePP)) was determined. An AvePP greater 
than 0.7 suggests clear classification of participants into 
that cluster.21 Cluster-specific probabilities of reporting 
of chest pain and SoB for each month allow profiles of 
the trajectory of CVD symptoms to be developed for each 
cluster. The clusters were then descriptively compared on 
the baseline covariates described earlier. 
As a sensitivity analysis, LCGA was repeated using 
participants completing the chest pain and SoB items 
on at least 2 monthly questionnaires. A further sensitivity 
analysis used multiple imputation to impute clusters for 
all baseline CVD respondents, with 50 imputations, and 
using baseline age, gender, BMI, anxiety, depression, PCS 
score, number of pain sites elsewhere and baseline chest 
pain, SoB and HF diagnosis in the imputation. All analysis 
was done using Stata V.14, Mplus V.7.3 and MLwiN V.2.35.
results
Patient demographics
Two thousand and eight hundred and fiftyeight patients 
with CVD were mailed the baseline questionnaire, of 
which 1696 (59%) responded. Six hundred and sixty-one 
(39%) baseline responders answered the chest pain and 
SoB items on between 5 and 10 monthly questionnaires 
and were included in the main analyses reported here. 
Compared with all other baseline responders, those in 
the analysis were younger (mean difference 2.3 years), 
had a higher proportion of males (68% vs 62%) and had 
a slightly lower prevalence of chest pain (42% vs 44%) 
and SoB (54% vs 58%) at baseline (table 1).
Table 1 Sample characteristics, n (%)
Invited at baseline
Baseline 
responders
At least 1 monthly 
response
At least 2 monthly 
responses*
At least 5 monthly 
responses†
n 2858 1696 871 777 661
Condition group
  IHD 2526 (88) 1501 (89) 783 (90) 701 (90) 603 (91)
  HF  332 (12)  195 (11)  88 (10)  76 (10)  58 (9)
Age
  <60 401 (14) 172 (10) 103 (12) 89 (11) 75 (11)
  60–69 782 (27) 463 (27) 265 (30) 241 (31) 201 (30)
  70–79 987 (35) 652 (38) 339 (39) 304 (39) 274 (41)
  80+ 688 (24) 409 (24) 164 (19) 143 (18) 111 (17)
Gender
  Male 1712 (60) 1059 (62) 574 (66) 514 (66) 447 (68)
  Female 1146 (40) 637 (38) 297 (34) 263 (34) 214 (32)
Baseline chest pain N/A 689 (44) 359 (44) 318 (43) 266 (42)
Baseline SoB N/A 942 (58) 495 (58) 430 (57) 354 (54)
*Population for sensitivity analysis.
†Population for main analysis.
HF, heart failure; IHD, ischaemic heart disease; SoB, shortness of breath.
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During the 10-month follow-up period, prevalence of 
chest pain during activity in all 4 weeks ranged from 11% 
to 13% by month and that of chest pain for 1–3 weeks 
from 23% to 28%. Monthly prevalence of SoB during 
activity in all 4 weeks ranged from 21% to 26% and SoB 
for 1–3 weeks from 34% to 37%.
Phase one: associations between baseline characteristics and 
chest pain
Unadjusted analysis showed increasing number of pain 
sites elsewhere, being anxious or depressed and having a 
worse PCS score were associated with an increase in risk 
of reporting chest pain in all 4 weeks in a month.
After adjustment for all covariates, an increasing 
number of pain sites (relative risk ratio (RRR) for 4+ vs 
none: 4.03, 95% CI 1.64 to 9.91) and being anxious or 
depressed (RRR: 3.31, 95% CI 1.89 to 5.79) were asso-
ciated with reporting chest pain in all 4 weeks in the 
previous month (table 2). The interactions of anxiety or 
depression and number of pain sites at baseline with time 
were not statistically significant.
Phase one: associations between baseline characteristics and SoB
Unadjusted analysis showed more pain sites elsewhere, 
being anxious or depressed, obesity, female gender and 
having a worse PCS score were associated with an increase 
in risk of reporting SoB during activity in all 4 weeks in 
the last month.
After adjustment for all covariates, increasing number 
of pain sites (RRR for 4+ vs none: 4.64, 95% CI 2.35 to 
9.18), being anxious or depressed (RRR: 4.10, 95% CI 
2.72 to 6.17) and obesity (RRR: 2.53, 95% CI 1.49 to 4.30) 
were associated with increased risk of reporting SoB in 
each of the previous 4 weeks, as were female gender and 
being over 80 years of age. There were no statistically 
significant interactions with time (table 3).
Phase one: -sensitivity analyses
Sensitivity analyses including those responding on 
at least 2 monthly questionnaires (n=777) and using 
multiple imputation did not change the findings 
(see online supplementary tables 1–4).
Phase two:- trajectories of chest pain and sob
The goodness of fit measures from the LCGA did not 
clearly suggest an optimal number of clusters of trajec-
tories of chest pain and SoB, although their values 
levelled off from the model with eight clusters (table 4). 
The six-cluster model had a lowest observed cluster size 
of 7% (n=47) of participants, compared with 4% (24 
Table 2 Associations between baseline characteristics and monthly chest pain (n=661)
Baseline characteristics
Monthly chest pain
1–3 weeks versus none 4 weeks versus none
Unadjusted
RRR (95% CI)
Adjusted*
RRR (95% CI)
Unadjusted
RRR (95% CI)
Adjusted*
RRR (95% CI)
Male 1 1 1 1
Female 1.50 (1.08 to 2.08) 1.20 (0.77 to 1.54)   1.48 (0.90 to 2.43) 1.29 (0.73 to 2.28)
Age
  <60 1 1 1 1
  60–69 1.35 (0.81 to 2.23) 1.23 (0.74 to 2.06) 0.64 (0.31 to 1.33) 0.65 (0.28 to 1.49)
  70–79 1.39 (0.85 to 2.27) 1.41 (0.86 to 2.34) 0.49 (0.24 to 0.99) 0.49 (0.21 to 1.11)
  80+ 1.25 (0.68 to 2.29) 1.18 (0.64 to 2.16) 0.42 (0.17 to 1.03) 0.47 (0.17 to 1.28)
BMI
  Normal 1 1 1 1
  Overweight 0.88 (0.60 to 1.28) 0.79 (0.54 to 1.15) 0.93 (0.53 to 1.65) 0.80 (0.42 to 1.51)
  Obese 0.95 (0.63 to  1.45) 0.67 (0.43 to 1.03) 1.77 (0.94 to 3.34) 0.74 (0.36 to 1.54)
PCS score (per unit) 0.95 (0.93 to0.96) – 0.89 (0.87 to 0.91) –
Not anxious or depressed 1 1 1 1
Anxious or depressed 2.55 (1.85 to 3.51) 2.32 (1.66 to 3.24) 5.42 (3.19 to 9.19) 3.31 (1.89 to 5.79)
Pain sites
  None 1 1 1 1
  1–3 3.38 (1.97 to 5.81) 3.01 (1.77 to 5.13) 1.19 (0.50 to 2.81) 1.24 (0.51 to 3.01)
  4+ 5.66 (3.32 to 9.66) 3.89 (2.25 to6.74) 6.16 (2.69 to 14.14) 4.03 (1.64 to 9.91)
Between-person
variance
– 2.39 – 7.07
Bold values mean statistically significant
*Adjusted for all presented variables.
BMI, body mass index; PCS, Physical Component Summary; RRR, relative risk ratio.
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participants) for the seven-cluster model, and 3% (20 
participants) for the model with eight clusters. Based on 
the goodness of fit measures, the size of clusters and their 
interpretation, the eight-cluster model was preferred 
(table 5).
Patients allocated to the largest cluster (n=166, 25%) 
generally reported no chest pain or SoB symptoms (with 
monthly probability 0.95 and above) in all the monthly 
questionnaires. Across clusters, in those reporting symp-
toms, SoB was more common than chest pain. One cluster 
Table 3 Associations between baseline characteristics and monthly shortness of breath (n=661)
Baseline characteristics
Monthly shortness of breath
1–3 weeks versus none 4 weeks versus none
Unadjusted
RRR (95% CI)
Adjusted*
RRR (95% CI)
Unadjusted
RRR (95% CI)
Adjusted*
Male 1 1 1 1
Female 1.84 (1.36 to2.49) 1.46 (1.07 to2.01) 2.58 (1.78 to 3.75) 1.81 (1.20 to 2.75)
Age
  <60 1 1 1 1
  60–69 1.30 (0.81 to 2.07) 1.18 (0.74 to 1.90) 1.10 (0.62 to 1.95) 0.92 (0.49 to 1.71)
  70–79 1.80 (1.14 to 2.83) 1.83 (1.15 to2.90) 1.40 (0.80 to 2.44) 1.72 (0.94 to 3.17)
  80+ 1.91 (1.10 to 3.31) 2.47 (1.41 to 4.34) 1.53 (0.77 to 3.02) 2.51 (1.19 to 5.26)
BMI
  Normal 1 1 1 1
  Overweight 1.25 (0.88 to 1.76) 1.28 (0.90 to 1.81) 1.02 (0.66 to 1.58) 1.03 (0.64 to 1.65)
  Obese 1.77 (1.20 to2.62) 1.67 (1.12 to2.51) 2.93 (1.80 to4.78) 2.53 (1.49 to 4.30)
PCS score (per unit) 0.93 (0.92 to0.94) – 0.87 (0.86 to0.89) –
Not anxious or depressed 1 1 1 1
Anxious or depressed 3.04 (2.26 to 4.08) 2.33 (1.70 to 3.19) 5.36 (3.67 to 7.82) 4.10 (2.72 to 6.17)
Pain sites
  None 1 1 1 1
  1–3 2.23 (1.41 to3.54) 1.98 (1.23 to3.17) 4.06 (2.20 to7.50) 3.50 (1.80 to 6.80)
  4+ 4.31 (2.74 to 6.80) 3.05 (1.88 to4.97) 8.90 (4.87 to16.29) 4.64 (2.35 to 9.18)
Between-person
variance
– 2.09 – 3.72
Bold values mean statistically significant.
*Adjusted for all presented variables.
BMI, body mass index; PCS, Physical Component Summary; RRR, relative risk ratio.
Table 4 Goodness of fit of the dual trajectory models with differing numbers of clusters
Clusters AIC BIC Adjusted BIC
Smallest class
(overall) (%)
AvePP*
(range)
1 23 241.43 23 277.38 23 251.98
2 17 999.11 18 066.52 18 018.89
3 16 185.44 16 284.30 16 214.45 16 0.98–0.98
4 15 088.50 15 218.82 15 126.74 15 0.95–0.99
5 14 310.02 14 471.80 14 357.50 9 0.94–0.99
6 14 018.94 14 212.17 14 075.64 7 0.93–0.98
7 13 820.48 14 045.17 13 886.42 4 0.92–0.98
8 13 701.00 13 957.15 13 776.17 3 0.89–0.99
9 13 628.19 13 915.79 13 712.59 0.1 0.88–1.00
*AvePP for participants allocated to cluster.
AIC, Akaike information criterion; AvePP, average posterior probability; BIC, Bayesian information criterion.
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of patients reported infrequent breathlessness symptoms 
(reporting SoB for up to 3 weeks on a median of 3 of the 
10 monthly questionnaires: n=93, 14%), another cluster 
of patients reported occasional breathlessness symptoms 
(reporting SoB for up to 3 weeks in a median of 8 out of 
the 10 months: n=83, 13%) and a third cluster of patients 
reported persistent breathlessness symptoms (reporting 
SoB in all of the last 4 weeks in all monthly question-
naires: n=52, 8%), but people in these three clusters 
rarely reported chest pain. The smallest cluster reported 
occasional chest pain, but rarely reported SoB (n=20, 
3%). Two clusters reported occasional (n=125, 19%) or 
frequent (no months without symptoms, n=75, 11%) 
pain alongside breathlessness. The most severe group 
of patients reported persistent SoB and pain over the 10 
months, that is, reported SoB and pain for all 4 weeks in 
all monthly questionnaires (n=47, 7%).
Patients in the clusters with both pain and SoB that 
was frequent or persistent had poorer baseline comorbid 
symptoms (anxiety and depression, and pain elsewhere) 
and worse physical health in general (table 6). Levels of 
obesity were higher in those with persistent SoB (with or 
without pain). The most severe group were younger than 
the other symptomatic groups.
Sensitivity analysis, including respondents with at least 
2 monthly responses, showed a similar distribution of 
participants across clusters (see online supplementary 
table 5). Multiple imputation of cluster membership for 
all baseline respondents reduced the percentage in the 
no symptoms cluster (25% to 22%) and increased the 
percentage in the frequent pain and SoB cluster (11% to 
14%) (see online supplementary table 6).
dIscussIon
summary
Using a prospective cohort study of patients with CVD, we 
found that potentially modifiable characteristics (weight, 
psychological health and number of painful body sites) 
influence the experience of both occasional and persistent 
chest pain and SoB during activity, and that eight distinct 
symptom trajectories are apparent, with breathlessness 
symptoms more common than chest pain.
Three of our identified clusters consisted of patients 
with stable conditions. The most common cluster 
(containing a quarter of our sample) reported no symp-
toms every month. By contrast, one cluster reported 
persistent chest pain and SoB every month, and another 
reported persistent SoB without chest pain every month. 
Symptoms of patients in the remaining clusters fluctuated 
more. We did not observe a cluster who improved or wors-
ened over the 10 months, which may reflect the prevalent 
rather than incident nature of the cohort.
Though chest pain and SoB may be considered a 
distinctive symptom of acute CVD conditions, such as 
myocardial infarction, a quarter of our prevalent CVD 
sample did not experience these symptoms at all, similar 
to a study of community recruited patients with HF from 
the UK.22 Chest pain and SoB commonly co-occurred, but 
SoB was more common and was reported without chest 
pain in three of our clusters (containing over a third of 
our cohort). We found a strong association between poor 
psychological health and both chest pain and SoB. Our 
findings are supported by previous cross-sectional studies 
that showed a correlation between SoB and depression 
both in US and Chinese secondary care HF samples.23 24 
Approximately two-thirds of patients with CVD in the most 
severe symptom clusters (frequent or persistent chest 
pain and SoB) had anxiety or depression. These results 
are supported by longitudinal research that reported 
poorer treatment outcomes in angina patients with 
chest pain and depression, compared with those without 
depression25 and that in angina patients with persistent 
symptoms, long-term anxiety and depression were more 
likely.26 Our research shows that the psychological health 
of patients with CVD, especially those with frequent chest 
pain and SoB, is poor. However, at present, our findings 
only indicate the association between chest pain, SoB and 
poor mental health. It remains unclear whether interven-
tions aimed at anxiety or depression would improve these 
CVD symptoms, though this does present a potential 
avenue for future research.
Patients with CVD who were obese at baseline were 
more likely to experience SoB compared with those of 
normal weight. This in line with other research and also 
demonstrates potential to improve this common CVD 
symptom. Bernhardt and Babb27 found that moderate 
weight loss in women who were obese at baseline was 
effective at reducing breathlessness during exertion.
We have shown that chest pain and SoB are associated 
with anxiety and depression and pain elsewhere, and 
addressing these characteristics may benefit both symp-
toms. Clark et al reported that improving (or diminishing) 
SoB after 2 years depended on whether pain resolved 
or diminished respectively.7 As a third of our sample 
reported both chest pain and SoB, these present a consid-
erable proportion of patients with CVD where future 
research may look to develop interventions towards a 
singular problem (eg, anxiety), which may also benefit 
the two symptoms.
Our clusters provide distinct patterns of symptom expe-
rience over time within a CVD population. Three-quarters 
of patients with CVD experienced either SoB or chest 
pain; however, approximately a third of our sample (35%) 
reported SoB only, either infrequently (14%), occasion-
ally (13%) or persistently (8%). These may represent a 
cluster of patients at greater risk of poor outcomes. In 
a large sample of US participants with coronary artery 
disease at baseline, the mortality rates were twice as high 
in patients with SoB compared with those with other 
symptoms and four times greater than in those with no 
symptoms at presentation.28 Symptoms such a chest pain 
and SoB may act as prognostic indicators for outcomes 
resulting in8 or from CVD,28 and therefore our findings 
present a range of likely trajectories to which future 
research may tailor interventions.
group.bmj.com on June 29, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Barnett LA, et al. BMJ Open 2017;7:e015857. doi:10.1136/bmjopen-2017-015857
Open Access 
Ta
b
le
 6
 
C
om
p
ar
is
on
 b
et
w
ee
n 
cl
us
te
rs
 o
n 
b
as
el
in
e 
so
ci
od
em
og
ra
p
hi
c 
an
d
 g
en
er
al
 h
ea
lth
 m
ea
su
re
s,
 n
 (%
) u
nl
es
s 
ot
he
rw
is
e 
st
at
ed
D
es
cr
ip
ti
o
n
C
lu
st
er
 1
C
lu
st
er
 2
C
lu
st
er
 3
C
lu
st
er
 4
C
lu
st
er
 5
C
lu
st
er
 6
C
lu
st
er
 7
C
lu
st
er
 8
N
o
 s
ym
p
to
m
s
In
fr
eq
ue
nt
 
S
o
B
O
cc
as
io
na
l 
ch
es
t 
p
ai
n
O
cc
as
io
na
l 
S
o
B
O
cc
as
io
na
l c
he
st
 
p
ai
n 
an
d
 S
o
B
Fr
eq
ue
nt
 c
he
st
 
p
ai
n 
an
d
 S
o
B
P
er
si
st
en
t 
S
o
B
P
er
si
st
en
t 
ch
es
t 
p
ai
n 
an
d
 S
o
B
N
um
b
er
 o
f p
at
ie
nt
s 
in
 c
lu
st
er
16
6 
(2
5)
93
 (1
4)
20
 (3
)
83
 (1
3)
12
5 
(1
9)
75
 (1
1)
52
 (8
)
47
 (7
)
Fe
m
al
e
33
 (2
0)
31
 (3
3)
5 
(2
5)
29
 (3
5)
43
 (3
4)
31
 (4
1)
22
 (4
2)
20
 (4
3)
A
ge
 
 <
60
26
 (1
6)
7 
(8
)
4 
(2
0)
9 
(1
1)
11
 (9
)
6 
(8
)
2 
(4
)
10
 (2
1)
 
 60
–6
9
59
 (3
6)
28
 (3
0)
5 
(2
5)
17
 (2
0)
42
 (3
4)
17
 (2
3)
17
 (3
3)
16
 (3
4)
 
 70
–7
9
59
 (3
6)
40
 (4
3)
9 
(4
5)
37
 (4
5)
53
 (4
2)
34
 (4
5)
24
 (4
6)
18
 (3
8)
 
 80
+
22
 (1
3)
18
 (1
9)
2 
(1
0)
20
 (2
4)
19
 (1
5)
18
 (2
4)
9 
(1
7)
3 
(6
)
B
M
I g
ro
up
 
 N
or
m
al
 w
ei
gh
t
50
 (3
1)
24
 (2
8)
10
 (5
0)
16
 (2
0)
30
 (2
6)
17
 (2
5)
10
 (2
0)
9 
(2
0)
 
 O
ve
rw
ei
gh
t
81
 (5
0)
47
 (5
5)
7 
(3
5)
39
 (4
9)
57
 (4
9)
29
 (4
3)
16
 (3
1)
14
 (3
2)
 
 O
b
es
e
31
 (1
9)
15
 (1
7)
3 
(1
5)
25
 (3
1)
29
 (2
5)
22
 (3
2)
25
 (4
9)
21
 (4
8)
M
ea
n 
P
C
S
 (S
D
)
47
.1
 (1
0.
26
)
39
.5
 (1
0.
89
)
39
.8
 (1
1.
4)
38
.3
 (1
0.
43
)
36
.9
3 
(9
.7
1)
28
.5
 (8
.9
1)
31
.0
 (9
.9
9)
24
.6
 (7
.0
5)
A
nx
io
us
 o
r 
d
ep
re
ss
ed
17
 (1
1)
20
 (2
2)
6 
(3
0)
32
 (4
0)
51
 (4
2)
48
 (6
9)
20
 (3
8)
29
 (6
3)
P
ai
n 
si
te
s
 
 N
on
e
38
 (2
3)
15
 (1
6)
2 
(1
0)
5 
(6
)
8 
(6
)
3 
(4
)
4 
(8
)
1 
(2
)
 
 1–
3 
si
te
s
83
 (5
0)
39
 (4
2)
8 
(4
0)
30
 (3
6)
45
 (3
6)
19
 (2
5)
25
 (4
8)
10
 (2
1)
 
 4+
 s
ite
s
45
 (2
7)
39
 (4
2)
10
 (5
0)
48
 (5
8)
72
 (5
8)
53
 (7
1)
23
 (4
4)
36
 (7
7)
B
M
I, 
b
od
y 
m
as
 in
d
ex
; P
C
S
, P
hy
si
ca
l C
om
p
on
en
t 
S
um
m
 a
ry
; S
oB
, s
ho
rt
ne
ss
 o
f b
re
at
h.
group.bmj.com on June 29, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 9Barnett LA, et al. BMJ Open 2017;7:e015857. doi:10.1136/bmjopen-2017-015857
Open Access
strengths and limitations
The strength of our study lies in its prospective cohort 
design that has used a large CVD sample from primary 
care to gain an insight into the monthly experience of 
chest pain and SoB symptom in this sample. This study 
was conducted within a UK primary care setting using 
monthly surveys from patients with a diagnosis of CVD, 
identified through electronic health records from 10 
general practices. Since these patients were identi-
fied from general practices across North Staffordshire, 
Stoke-on-Trent and Cheshire, they represent a sample 
generalisable to the UK primary care population.29
This is the first research to examine monthly trajecto-
ries of these symptoms in CVD patients.
There are several limitations to our work. First, due to 
the prospective nature of our research, there was attri-
tion during the follow-up period. Those in the monthly 
analysis were slightly younger and more likely to be 
male than all those responding at baseline. Related to 
attrition, our use of multiple imputation may be limited 
as we are unable to determine if missing values are 
truly missing at random. In the monthly questionnaire, 
our definitions of chest pain and SoB were based on a 
single question for each. Though using a short monthly 
questionnaire improved the month-on-month response 
rates, such a simple definition may limit the accuracy 
of patient responses. The questions related to chest 
pain and SoB that occurred during activity; however, 
it is possible that the symptoms may be non-cardiovas-
cular in origin. We also did not identify the number or 
duration of symptom episodes other than in how many 
weeks they had occurred in the last month. However, 
no matter the specific cause of the chest pain or SoB, 
patients with CVD are experiencing these symptoms, 
and therefore these need to be addressed.
conclusions
Several modifiable patient characteristics (weight, 
psychological health and number of other painful body 
sites) are associated with the experience of both occa-
sional and weekly chest pain and SoB during activity. 
Future interventions to improve CVD symptom experi-
ence may wish to target these covariates. By identifying 
trajectories of symptoms over time, care may be better 
tailored to improve outcomes in those patients with 
CVD at greatest risk of worse symptoms and disease 
progression.
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